Volume 96, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Dihydroartemisinin–piperaquine (DP) is recommended for the treatment of uncomplicated malaria, used in efforts to contain artemisinin resistance, and increasingly considered for mass drug administration. Because of the narrow therapeutic dose range and available tablet strengths, the manufacturers and World Health Organization recommended regimens involve breaking tablets into halves to accurately dose children according to body weight. Use of tablet fractions in programmatic settings under tropical conditions requires a highly stable product; however, the stability of DP tablet fractions is unknown. We aged full and half DP (Eurartesim) tablets in a stability chamber at 30°C and 70% humidity level. The active pharmaceutical ingredients dihydroartemisinin and piperaquine remained at ≥ 95% over the 3 months' period of ageing in light and darkness. These findings are reassuring for DP, but highlight the need to assess drug stability under real-life settings during the drug development process, particularly for key drugs of global disease control programs.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Gerardin J, Eckhoff P, Wenger EA, , 2015. Mass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination. BMC Infect Dis 15: 144.[Crossref] [Google Scholar]
  2. Nankabirwa JI, Wandera B, Amuge P, Kiwanuka N, Dorsey G, Rosenthal PJ, Brooker SJ, Staedke SG, Kamya MR, , 2014. Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. Clin Infect Dis 58: 14041412.[Crossref] [Google Scholar]
  3. Cisse B, Cairns M, Faye E, NDiaye O, Faye B, Cames C, Cheng Y, NDiaye M, AC, Simondon K, Trape JF, Faye O, NDiaye JL, Gaye O, Greenwood B, Milligan P, , 2009. Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. PLoS One 4: e7164.[Crossref] [Google Scholar]
  4. Madanitsa M, Kalilani L, Mwapasa V, van Eijk AM, Khairallah C, Ali D, Pace C, Smedley J, Thwai KL, Levitt B, Wang D, Kang'ombe A, Faragher B, Taylor SM, Meshnick S, Ter Kuile FO, , 2016. Scheduled intermittent screening with rapid diagnostic tests and treatment with dihydroartemisinin-piperaquine versus intermittent preventive therapy with sulfadoxine-pyrimethamine for malaria in pregnancy in Malawi: an open-label randomized controlled trial. PLoS Med 13: e1002124.[Crossref] [Google Scholar]
  5. Desai M, Gutman J, L'Lanziva A, Otieno K, Juma E, Kariuki S, Ouma P, Were V, Laserson K, Katana A, Williamson J, ter Kuile FO, , 2015. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet 386: 25072519.[Crossref] [Google Scholar]
  6. Sigma-Tau Industrie Farmaceutiche Riunite s.p.a., 2011. Eurartesim: Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001199/WC500118113.pdf. Accessed September 19, 2016. [Google Scholar]
  7. World Health Organization (WHO), 2015. Guidelines for the Treatment of Malaria, 3rd edition. Geneva, Switzerland: WHO. Available at: http://www.who.int/malaria/publications/atoz/9789241549127/en/. Accessed September 19, 2016. [Google Scholar]
  8. World Health Organization, 2009. Technical Consultation on the Use of Pharmacokinetic Analyses for Paediatric Medicine Development. Available at: http://www.who.int/childmedicines/progress/Pharmacokinetic_June2009.pdf. Accessed September 9, 2016. [Google Scholar]
  9. World Health Organization, 2009. Stability Testing of Active Pharmaceutical Ingredients and Finished Pharmaceutical Products. WHO Technical Report Series, No. 953. Annex 2. Geneva, Switzerland: WHO. Available at: http://apps.who.int/medicinedocs/en/d/Js19133en/. Accessed November 10, 2016. [Google Scholar]
  10. Kaur H, Allan EL, Mamadu I, Hall Z, Ibe O, El Sherbiny M, van Wyk A, Yeung S, Swamidoss I, Green MD, Dwivedi P, Culzoni MJ, Clarke S, Schellenberg D, Fernández FM, Onwujekwe O, , 2015. Quality of artemisinin-based combination formulations for malaria treatment: Prevalence and risk factors for poor quality medicines in public facilities and private sector drug outlets in Enugu, Nigeria. PLoS One 10: e0125577.[Crossref] [Google Scholar]
  11. Hall Z, Allan EL, van Schalkwyk DA, van Wyk A, Kaur H, , 2016. Degradation of artemisinin-based combination therapies under tropical conditions. Am J Trop Med Hyg 94: 9931001.[Crossref] [Google Scholar]
  12. Suleman S, Vandercruyssen K, Wynendaele E, D'Hondt M, Bracke N, Duchateau L, Burvenich C, Peremans K, De Spiegeleer B, , 2013. A rapid stability-indicating, fused-core HPLC method for simultaneous determination of beta-artemether and lumefantrine in anti-malarial fixed dose combination products. Malar J 12: 145.[Crossref] [Google Scholar]
  13. Vandercruyssen K, D'Hondt M, Vergote V, Jansen H, Burvenich C, De Spiegeleer B, , 2014. LC–UV/MS quality analytics of paediatric artemether formulations. J Pharm Anal 4: 3752.[Crossref] [Google Scholar]
  14. Verbeken M, Suleman S, Baert B, Vangheluwe E, Van Dorpe S, Burvenich C, Duchateau L, Jansen FH, De Spiegeleer B, , 2011. Stability-indicating HPLC-DAD/UV-ESI/MS impurity profiling of the anti-malarial drug lumefantrine. Malar J 10: 51.[Crossref] [Google Scholar]

Data & Media loading...

Supplementary PDF

  • Received : 19 Sep 2016
  • Accepted : 10 Oct 2016
  • Published online : 08 Feb 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error